Login / Signup

Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease.

Michael Malek AhmadiThomas G BeachEdward ZamriniCharles H AdlerMarwan N SabbaghHolly A ShillSandra A JacobsonChristine M BeldenRichard J CaselliBrian K WoodruffSteven Z RapscakGeoffrey L AhernJiong ShiJohn N CavinessErika Driver-DunckleyShyamal H MehtaDavid R ShprecherBryan M SpannPierre TariotKathryn J DavisKathy E LongLisa R NicholsonAnthony IntorciaMichael J GlassJessica E WalkerMichael CallanJasmine CurryBrett CutlerJavon OliverRichard ArceDouglas G WalkerLih-Fen LueGeidy E SerranoLucia I SueKewei ChenEric M Reiman
Published in: PloS one (2019)
The probable cause of LBD clinical detection failure is the lack of a sufficient set of characteristic core clinical features. Core DLB clinical features were not more common in AD-LB as compared to ADD. Clinical identification of ADD with LBD would allow stratified analyses of ADD clinical trials, potentially improving the probability of trial success.
Keyphrases
  • mild cognitive impairment
  • cognitive decline
  • clinical trial
  • phase ii
  • study protocol
  • parkinson disease
  • randomized controlled trial